Baker Brothers portfolio

Baker Bros. Advisors · Julian and Felix Baker · Biotechnology specialist

Baker Bros. Advisors's 13F filing for Q2 2026, filed with the SEC on August 14, 2026, reports $20B across 84 US-listed positions. The largest holding is INCY at 17.5% of the portfolio; the ten largest make up 73%. The largest buy last quarter was RVMD ($353.6M).

Reported value
$20B
Positions
84
In the top 10
73%
Quarter
Q2 2026
filed Aug 14

Key facts

13F portfolio value
$20BQ2 2026
Positions
84
Largest holding
INCY 17.5%
Top 10 share
73%
New positions
8since Q1 2026
Sold out
8
Filed
Aug 14, 2026
Next 13F due
Nov 16, 2026Q3 2026

Holdings as of (Q2 2026), filed with the SEC on . Changes are measured against the filing for Mar 31, 2026. Source: SEC EDGAR, Form 13F-HR of Baker Bros. Advisors (CIK 1263508).

Prices as of .

Compared with Q1 2026, Baker Brothers opened 8 new positions (FTH, CYTK, NTLA…), added to 16, trimmed 7, sold out of 8 (ABVX, SYRE, Centessa Pharmaceuticals PLC…).

By sector, Health Care is the largest at 79% of the reported portfolio; 21% is in securities with no sector on file.

49 of the 84 positions listed have been in every one of the last 9 quarterly filings.

Baker Brothers top holdings: stocks in the Q2 2026 13F

Baker Brothers holdings, Q2 2026
#StockSectorShare of portfolioValueSharesReported pricePrice nowSince period endHeldLast quarter
1Incyte CorpINCYHealth Care17.5%$3.5B30.76M$113.36$120.54 6.3% up9+ qtrs▲ Added 0.06%
2Beone Medicines LtdONC · SPONSORED ADSHealth Care12.6%$2.5B8.8M$284.97$410.40 44.0% up9+ qtrs▲ Added 0.03%
3Revolution Medicines IncRVMDHealth Care10.7%$2.1B11.44M$187.28$164.37 12.2% down9+ qtrs▲ Added 20%
4Madrigal Pharmaceuticals IncMDGLHealth Care5.77%$1.2B2.14M$536.95$427.40 20.4% down9+ qtrs▲ Added 0.07%
5Acadia Pharmaceuticals IncACAD—5.44%$1.1B42.91M$25.30$18.27 27.8% down9+ qtrs▲ Added 0.04%
6Kymera Therapeutics IncKYMRHealth Care4.98%$992.7M8.66M$114.67$122.19 6.6% up9+ qtrsNo change
7Insmed IncINSMHealth Care4.70%$937.8M8.8M$106.62$119.71 12.3% up9+ qtrs▲ Added 19%
8Celcuity IncCELC—4.15%$828.2M7.92M$104.62$58.68 43.9% down9+ qtrsNo change
9Kodiak Sciences IncKODHealth Care3.89%$776.1M19.92M$38.96$96.75 148.3% up9+ qtrsNo change
10Rhythm Pharmaceuticals IncRYTMHealth Care3.12%$622.3M5.6M$111.03$113.25 2.0% up9+ qtrsNo change
11Praxis Precision MedicinesPRAXHealth Care2.94%$587M1.75M$334.79$309.67 7.5% down9+ qtrsNo change
12Alkermes PLCALKS · SHSHealth Care2.63%$524.6M10.01M$52.39$45.55 13.1% down9+ qtrsNo change
13Summit Therapeutics IncSMMTHealth Care2.39%$477.7M32.79M$14.57$10.91 25.1% down9+ qtrs▼ Reduced 9.9%
14Grail IncGRALHealth Care1.38%$275M4.03M$68.27$103.69 51.9% up7 qtrsNo change
15Abcellera Biologics IncABCL—1.30%$259.1M33.01M$7.85$11.11 41.5% up9+ qtrs▲ Added 9.0%
16Immunovant IncIMVTHealth Care1.05%$209.4M5.44M$38.53$33.23 13.8% down9+ qtrs▼ Reduced 0.4%
17IDEAYA Biosciences IncIDYA—0.94%$186.7M5.01M$37.27$27.09 27.3% down9+ qtrs▲ Added 27%
18Kiniksa Pharmaceuticals InternationalKNSA · ORD SHS CL AHealth Care0.91%$181.3M2.83M$63.95$94.56 47.9% up9+ qtrs▲ Added 0.3%
19Roivant Sciences LtdROIV · SHSHealth Care0.84%$166.9M4.72M$35.39$38.33 8.3% up9+ qtrs▼ Reduced 3.1%
20Arrowhead PharmaceuticalsARWRHealth Care0.81%$162.4M1.99M$81.51$43.51 46.6% down5 qtrsNo change
21Ionis Pharmaceuticals IncIONSHealth Care0.81%$162.4M2.05M$79.29$27.02 65.9% down4 qtrsNo change
22Edgewise Therapeutics IncEWTXHealth Care0.75%$150.4M3.7M$40.63$42.15 3.7% up9+ qtrs▼ Reduced 44%
23Replimune Group IncREPL—0.61%$122.3M11.05M$11.07$20.55 85.6% up9+ qtrsNo change
24Nurix Therapeutics IncNRIX—0.57%$113M4.66M$24.26$14.39 40.7% down9+ qtrsNo change
25Stoke Therapeutics IncSTOK—0.55%$109.2M3.34M$32.72$26.61 18.7% down9+ qtrsNo change
26Monte Rosa Therapeutics IncGLUE—0.53%$105.2M4.35M$24.20$9.06 62.6% down9+ qtrsNo change
27Immatics N.V.IMTX · SHS—0.48%$96.3M9.51M$10.13$6.18 39.0% down9+ qtrs▼ Reduced 13%
28Denali Therapeutics IncDNLI—0.48%$96M3.73M$25.72$17.96 30.2% down9+ qtrs▲ Added 0.07%
29
Crinetics Pharmaceuticalsno ticker on file
—0.44%$88M2.35M$37.42——5 qtrsNo change
30Dianthus Therapeutics IncDNTHHealth Care0.42%$83.1M852.16K$97.48$87.29 10.5% down5 qtrsNo change
31Structure Therapeutics IncGPCR · SPONSORED ADS—0.39%$76.9M1.43M$53.67$18.34 65.8% down8 qtrsNo change
32
Celcuity Incno ticker on file · NOTE 2.75% 8/1/2031
—0.35%$69.2M————4 qtrs—
33Rapport Therapeutics IncRAPP—0.32%$64.5M1.55M$41.67$24.05 42.3% down5 qtrsNo change
34Alumis IncALMS—0.28%$56.6M2.01M$28.14$4.94 82.4% down9+ qtrsNo change
35Prelude Therapeutics IncPRLD—0.27%$54M10.12M$5.33$3.34 37.4% down9+ qtrsNo change
36Relay Therapeutics IncRLAY—0.27%$52.9M2.83M$18.71$17.01 9.1% down9+ qtrs▲ Added 144%
37Mirum Pharmaceuticals IncMIRMHealth Care0.26%$52.2M445.98K$117.07$90.59 22.6% down2 qtrsNo change
38Bicycle Therapeutics PlcBCYC · SPONSORED ADS—0.23%$46.2M10.89M$4.24$3.17 25.2% down9+ qtrsNo change
39Enliven Therapeutics IncELVN—0.23%$45.9M905.19K$50.75$47.30 6.8% down9+ qtrsNo change
40Celldex Therapeutics IncCLDX—0.22%$44M1.18M$37.21$28.16 24.3% down9+ qtrs▲ Added 78%
41Viridian Therapeutics IncVRDN—0.22%$43.8M2.38M$18.37$29.76 62.0% up5 qtrs▲ Added 21%
42Design Therapeutics IncDSGN—0.19%$38.8M2.68M$14.47$9.85 31.9% down9+ qtrs▲ Added 3.6%
43Entrada Therapeutics IncTRDA—0.19%$37.3M5.07M$7.36$5.29 28.1% down9+ qtrsNo change
44Faeth Therapeutics IncFTH—0.16%$32.2M1.29M$25.00$8.73 65.1% down1 qtrNew
45Aktis Oncology IncAKTS—0.16%$32.1M996.35K$32.23$16.26 49.6% down2 qtrsNo change
46Neurogene IncNGNE—0.16%$31.2M991.69K$31.45$22.71 27.8% down9+ qtrsNo change
47Jade Biosciences IncJBIO—0.14%$27.3M1.23M$22.22$15.09 32.1% down3 qtrs▼ Reduced 25%
48Taysha Gene Therapies IncTSHA—0.14%$27.3M4M$6.81$4.03 40.8% down9+ qtrsNo change
49Arcus Biosciences IncRCUS—0.13%$26M844.82K$30.83$16.58 46.2% down3 qtrs▲ Added 103%
50Disc Medicine IncIRON—0.13%$25.6M349.66K$73.14$76.62 4.8% up7 qtrsNo change
51Absci CorpABSI—0.12%$24.7M2.13M$11.59$7.56 34.8% down3 qtrsNo change
52Generate Biomedicines IncGENB—0.12%$24M1.42M$16.87$9.97 40.9% down2 qtrsNo change
53Dbv Technologies S A SponsoredDBVT · SPONSORED ADS—0.12%$24M1.46M$16.40$9.91 39.6% down9+ qtrsNo change
54Xenon Pharmaceuticals IncXENE—0.11%$22.3M370.21K$60.36$38.49 36.2% down9+ qtrsNo change
55Tectonic Therapeutic IncTECX—0.11%$20.9M607.79K$34.38$20.41 40.6% down6 qtrsNo change
56Cerus CorpCERS—0.09%$18.7M6.4M$2.92$1.92 34.2% down9+ qtrs▼ Reduced 36%
57CytomX Therapeutics IncCTMX—0.09%$18.7M4.98M$3.75$1.98 47.3% down5 qtrsNo change
58Dyne Therapeutics IncDYN—0.09%$18.1M813.45K$22.21$16.38 26.3% down3 qtrsNo change
59Cytokinetics IncCYTKHealth Care0.09%$18M211.27K$85.19$51.87 39.1% down1 qtrNew
60Xencor IncXNCR—0.09%$17.7M1.1M$16.10$34.75 115.8% up9+ qtrsNo change
61Sionna Therapeutics IncSION—0.09%$17.6M400K$43.99$3.08 93.0% down6 qtrsNo change
62Intellia Therapeutics IncNTLA—0.08%$15.7M930.23K$16.92$9.87 41.7% down1 qtrNew
63Parabilis Medicines IncPBLS—0.07%$13.7M500K$27.37$28.12 2.7% up1 qtrNew
64Maplight Therapeutics IncMPLT—0.07%$13.1M364.71K$35.84$6.63 81.5% down3 qtrsNo change
65Avalyn Pharma IncAVLN—0.06%$11.5M350K$32.92$28.09 14.7% down1 qtrNew
66Evommune IncEVMN—0.06%$11.3M847.39K$13.29$7.05 47.0% down2 qtrsNo change
67BioNTech SEBNTX · SPONSORED ADSHealth Care0.06%$11.1M119.74K$93.05$85.33 8.3% down7 qtrsNo change
68Tango Therapeutics IncTNGX—0.05%$10.4M333.33K$31.26$22.80 27.1% down1 qtrNew
69Avalo Therapeutics IncAVTX—0.05%$10.2M550K$18.48$7.08 61.7% down1 qtrNew
70Sera Prognostics IncSERA · CLASS A COM—0.05%$10M5.5M$1.82$1.92 5.5% up9+ qtrsNo change
71Verastem IncVSTM—0.05%$9.5M2.5M$3.82$7.59 98.6% up2 qtrs▲ Added 327%
72Sagimet Biosciences IncSGMT—0.04%$7.4M953K$7.73$10.01 29.4% up9+ qtrsNo change
73Eikon Therapeutics IncEIKN—0.04%$7.2M555.56K$13.05$5.25 59.8% down2 qtrsNo change
74LB Pharmaceuticals IncLBRX—0.03%$6.5M200K$32.46$40.13 23.6% up4 qtrsNo change
75vTv Therapeutics IncVTVT · CL A—0.03%$5.6M148.31K$37.65$17.05 54.7% down9+ qtrsNo change
76Wave Life Sciences LtdWVE · SHS—0.02%$4.8M822.64K$5.81$2.91 49.9% down8 qtrsNo change
77Protara Therapeutics IncTARA—0.02%$3.7M971.61K$3.82$2.35 38.6% down9+ qtrsNo change
78TScan Therapeutics IncTCRX—0.01%$2.7M2.78M$0.9801$0.1414 85.6% down9+ qtrsNo change
79Immunome IncIMNM—0.01%$1.2M55.31K$21.19$17.36 18.1% down1 qtrNew
80Skye Bioscience IncSKYE—0.01%$1.1M1.58M$0.6933$1.09 57.2% up9+ qtrsNo change
81Sana Biotechnology IncSANA—0.01%$1.1M310.48K$3.49$1.89 46.0% down9+ qtrsNo change
82Aligos Therapeutics IncALGS—0.00%$479.2K83.06K$5.77$1.44 75.0% down9+ qtrsNo change
83Tyra Biosciences IncTYRA—0.00%$338.8K10.61K$31.94$19.88 37.8% down9+ qtrsNo change
84
Surrozen Incno ticker on file · W EXP 8/11/2026
—0.00%$13.8K833.33K$0.0165——9+ qtrsNo change

Baker Brothers latest buys (Q2 2026)

  • RVMD ▲ Added 20%$353.6M
  • INSM ▲ Added 19%$146.6M
  • IDYA ▲ Added 27%$39.6M
  • FTH New$32.2M
  • RLAY ▲ Added 144%$31.2M
  • ABCL ▲ Added 9.0%$21.5M
  • CLDX ▲ Added 78%$19.2M
  • CYTK New$18M
  • NTLA New$15.7M
  • PBLS New$13.7M

Baker Brothers latest sells (Q2 2026)

  • EWTX ▼ Reduced 44%$116.8M
  • ABVX Sold$97.5M
  • SMMT ▼ Reduced 9.9%$52.5M
  • SYRE Sold$50.4M
  • Centessa Pharmaceuticals PLC Sold$26.6M
  • IMCR Sold$22.1M
  • CTNM Sold$18.6M
  • ARGX Sold$18.4M
  • IMTX ▼ Reduced 13%$14.3M
  • CMPS Sold$13M

Every buy and sell in Baker Brothers' Q2 2026 13F →

By sector

Baker Brothers portfolio by sector, Q2 2026
SectorShare of portfolioValuePositions
Health Care78.6%$15.7B22
No sector on file21.4%$4.3B62

8 quarterly filings on file for Baker Bros. Advisors, back to Q3 2024: reported value, position counts, and every buy and sell quarter by quarter.

Filing history →All Q2 2026 13F filings →

Questions about Baker Brothers' portfolio

What stocks does Baker Brothers own?

According to Baker Bros. Advisors' 13F filing for Q2 2026, the largest of its 84 US-listed positions are INCY (17.5%), ONC (12.6%), RVMD (10.7%), MDGL (5.8%) and ACAD (5.4%). A 13F shows long positions only, as of the quarter's end.

What is Baker Brothers' largest holding?

INCY (Incyte Corp), worth $3.5B at the end of Q2 2026, or 17.5% of the $20B Baker Bros. Advisors reported.

What did Baker Brothers buy last quarter?

In Q2 2026, compared with the filing for Q1 2026, the largest purchases were RVMD (added, $353.6M), INSM (added, $146.6M), IDYA (added, $39.6M), FTH (new position, $32.2M) and RLAY (added, $31.2M).

What did Baker Brothers sell last quarter?

In Q2 2026 the largest sales were EWTX (reduced, $116.8M), ABVX (sold out, $97.5M), SMMT (reduced, $52.5M), SYRE (sold out, $50.4M) and Centessa Pharmaceuticals PLC (sold out, $26.6M), against the filing for Q1 2026.

How much is Baker Brothers' portfolio worth?

Baker Bros. Advisors reported $20B in 84 US-listed positions for Q2 2026, valued at the quarter's end and filed on August 14, 2026. That is the 13F portfolio only: no cash, short positions or most shares listed outside the US.

When does Baker Brothers file the next 13F?

The 13F for Q3 2026, the quarter ending September 30, 2026, was due by November 16, 2026: 45 days after the quarter ends, or the next business day. The latest filing on file here is for Q2 2026, filed on August 14, 2026.

Which sectors does Baker Brothers own?

Health Care 78.6% of the reported portfolio, with 21.4% in securities that have no sector on file here (funds, smaller companies, positions without a ticker).

How long has Baker Brothers held these stocks?

Counting consecutive quarterly filings up to Q2 2026: INCY 9+, ONC 9+, RVMD 9+, MDGL 9+, ACAD 9+, KYMR 9+. “9+” means the position is in every filing looked at, so it may go back further.

Learn

Cite this page

Funkfolio, “Baker Brothers portfolio: Baker Bros. Advisors 13F holdings (Q2 2026)”, data as of 14 August 2026. https://funkfolio.com/gurus/baker-brothers

Underlying data: SEC EDGAR, Form 13F-HR of Baker Bros. Advisors (CIK 1263508) for the period ending June 30, 2026.

Source: SEC EDGAR, Form 13F-HR for Baker Bros. Advisors (CIK 1263508), period ending Jun 30, 2026, filed Aug 14, 2026. “Last quarter” compares share counts with the filing for Mar 31, 2026. “Reported price” is the position's reported value divided by its shares — the price the filing implies for the period end. “Price now” is from Yahoo Finance and can be delayed 15 minutes or more; “since period end” sets the two side by side and is left blank where the reported price falls outside the stock's 52-week range, which points to a share split since. A split small enough to stay inside that range is not caught, and dividends are not counted. Sectors are those of the ranked companies on this site; funds, smaller companies and positions without a ticker have none. “Held” counts consecutive quarterly filings the position appears in, out of the 9 looked at. A buy or sell is sized as the shares moved at the price the filing implies; a position sold out at its value in the previous filing. Filings can be 45 days old when published; this is not a live portfolio and not advice.